

A Systematic Review and Meta-Analysis on the Effectiveness of Bivalent mRNA Booster Vaccines against Omicron Variants

Shangchen Song^{1,†}, Zachary J. Madewell^{1,†}, Mingjin Liu², Yu Miao², Shaolin Xiang², Yanan Huo³, Shoumi Sarkar¹, Amily Chowdhury⁴, Ira M. Longini, Jr.^{1,#}, Yang Yang^{2,#,*}

¹ Department of Biostatistics, College of Public Health and health Professions, University of Florida, Gainesville, FL, USA

² Department of Statistics, Franklin College of Arts and Sciences, University of Georgia, Athens, GA, USA

³ Gilead Sciences, Inc, Foster City, CA, USA

⁴ Department of Computer Science, Franklin College of Arts and Sciences, University of Georgia, Athens, GA, USA

[†] These authors share first authorship

[#] These authors share senior authorship

* Correspondence should be addressed to:

Prof. Yang Yang

Email: yang.yang4@uga.edu

Keywords: Bivalent; Omicron; Vaccine Effectiveness; Meta-Analysis; Infection; Severe disease

ABSTRACT

Background: A global shift to bivalent mRNA vaccines is ongoing to counterbalance diminishing monovalent vaccine effectiveness (VE) due to the evolution of SARS-CoV-2 variants, yet substantial variation in the bivalent VE exists across studies and a complete picture is lacking.

Methods: We searched papers evaluating SARS-CoV-2 bivalent mRNA vaccines on PubMed, Web of Science, Cochrane Library, Google Scholar, Embase, Scopus, bioRxiv, and medRxiv published from September 1st, 2022, to November 8th, 2023. Pooled VE against Omicron-associated infection and severe events was estimated in reference to unvaccinated, ≥ 2 monovalent doses, and ≥ 3 monovalent doses.

Results: From 630 citations identified, 28 studies were included, involving 55,393,303 individuals. Bivalent boosters demonstrated superior protection against symptomatic or any infection compared to unvaccinated, ≥ 2 monovalent doses, and ≥ 3 monovalent doses, with corresponding relative VE estimated as 53.5% (95% CI: -22.2-82.3%), 30.8% (95% CI: 22.5-38.2%), and 28.4% (95% CI: 10.2-42.9%) for all ages, and 22.5% (95% CI: 16.8-39.8%), 31.4% (95% CI: 27.7-35.0%), and 30.6% (95% CI: -13.2-57.5%) for adults ≥ 60 years old. Pooled bivalent VE estimates against severe events were higher, 72.9% (95% CI: 60.5-82.4%), 57.6% (95% CI: 42.4-68.8%), and 62.1% (95% CI: 54.6-68.3%) for all ages, and 72.0% (95% CI: 51.4-83.9%), 63.4% (95% CI: 41.0-77.3%), and 60.7% (95% CI: 52.4-67.6%) for adults ≥ 60 years old, compared to unvaccinated, ≥ 2 monovalent doses, and ≥ 3 monovalent doses, respectively.

Conclusions: Bivalent boosters demonstrated higher VE against severe outcomes than monovalent boosters across age groups, highlighting the critical need for improving vaccine coverage, especially among the vulnerable older subpopulation.

45 **Introduction**

46 The emergence of the SARS-CoV-2 Omicron (B.1.1.529) variant in late 2022 significantly
47 undermined previous control measures in the continuing COVID-19 pandemic. Despite significant progress in
48 vaccination efforts worldwide, Omicron continues to pose a substantial threat, causing a significant number of
49 severe COVID-19 cases and fatalities due to continuously evolving immune escape. Monovalent mRNA
50 vaccines, initially designed for ancestral SARS-CoV-2 variants, demonstrated high effectiveness in preventing
51 severe COVID-19 caused by the Omicron variants [1,2]. One or two monovalent mRNA booster doses also
52 reduced hospitalizations and fatalities [3]. However, their effectiveness waned over time, particularly against
53 Omicron [4,5]. The Omicron sub-lineages from BA.1 to BA.5 and subsequent variants such as XBB.1.5, EG.5,
54 and FL.1.5.1 showcased the virus's adaptability through genetic mutations in the spike protein, making it
55 increasingly distinct from the original wild type [6]. Laboratory studies demonstrated that antibodies were less
56 effective at neutralizing these emerging subvariants compared to ancestral variants [7,8].

57 In response to reduced effectiveness of monovalent boosters, bivalent mRNA booster vaccines
58 containing spike sequences from the original SARS-CoV-2 strain and Omicron subvariants (BA.1 or BA.4-5)
59 emerged as a potential strategy to enhance protection against severe clinical outcomes. Laboratory studies
60 demonstrated that bivalent vaccines significantly increased neutralizing activity against subvariants like BA.4,
61 BA.5, BA.2.75, BQ.1.1, and XBB compared to the monovalent vaccines [9,10]. On September 1, 2022, the
62 Advisory Committee on Immunization Practices (ACIP) recommended these vaccines to address the reduced
63 effectiveness of monovalent vaccines [11]. The U.S. Food and Drug Administration (FDA) subsequently
64 approved Moderna and Pfizer-BioNTech bivalent formulations as single booster doses for individuals who
65 completed primary vaccination series or received monovalent boosters [12]. Since September 2022, many
66 countries have transitioned from monovalent boosters to bivalent boosters.

67 Recent studies increasingly demonstrate the higher effectiveness for bivalent boosters compared to
68 monovalent vaccines against infection and severe disease [13–15]. Meta-analyses provide an integrative
69 assessment of the effectiveness of bivalent boosters by aggregating data from multiple studies, enhancing
70 statistical robustness and generalizability, while controlling for differences between individual studies. One
71 review and case study reported vaccine effectiveness (VE) for bivalent boosters against hospitalization and
72 infection, but was limited to a few early studies [16]. Herein, we synthesize contemporary literature to report
73 absolute and relative VE of bivalent boosters against infection and severe COVID-19 compared to no
74 vaccination, two or more monovalent doses, and three or more monovalent doses, respectively.

75 76 **Methods**

77 This analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses
78 (PRISMA) reporting guidelines.

79

80 *Data Sources and Searches*

81 We systematically searched databases and platforms including PubMed, Web of Science, Cochrane
82 Library, Google Scholar, Embase, Scopus, and preprint servers (bioRxiv and medRxiv) for papers published
83 between September 1st, 2022 and November 8th, 2023. We applied Boolean combinations of the following
84 keywords to identify relevant publications: “SARS-CoV-2”, “COVID-19”, “2019nCoV”, “bivalent booster”,
85 “effectiveness”, “efficacy”, “test-negative”, “case-control”, “cohort study”, “Omicron”, “infection”,
86 “infected”, “hospitalization”, “hospital admission”. Details about the search procedures are available in
87 Supplementary material A.1. Publication language was not restricted, and reference lists of selected papers
88 were also screened for additional studies.

89

90 *Study Selection*

91 Studies were chosen based on the PICOS (Participant, Intervention, Comparator, Outcome, Study
92 Type) criteria [17] as detailed in Supplementary Material A.2. We focused on original research using
93 observational studies, e.g., test-negative design study or cohort study, that reported estimates for the
94 effectiveness of COVID-19 bivalent boosters against Omicron-related infections or severe events in reference
95 to either no vaccination or monovalent vaccine doses. The COVID-19 bivalent boosters include BA.1 type and
96 BA.4/BA.5 type mRNA vaccines manufactured by Pfizer-BioNTech and Moderna. We excluded studies that
97 (i) did not assess VE (e.g., evaluated neutralizing antibodies); (ii) targeted special populations (e.g., patients
98 with kidney disease); (iii) focused on relative VE between different types or doses of bivalent vaccines; (iv)
99 reported VE results for a mixture of bivalent and monovalent vaccines (unless bivalent representation was
100 90% or higher); or (v) examined outcomes unrelated to COVID-19. Our analysis included all available age
101 groups, and we did not seek additional data from authors.

102 After duplicates were removed, studies were initially sifted based on titles and abstracts by three
103 independent teams, each with three researchers. Full texts of potential matches were then independently
104 reviewed by the same three teams. Any disagreements were discussed until a consensus was reached. Preprints
105 were checked and updated with their most recently published version if available as of January 5th, 2024.
106 Zotero was used for literature management.

107

108 *Data Extraction and Quality Assessment*

109 The following information was independently extracted from the included studies: title, authors,
110 publishing journal and year, study region, duration and design, statistical method, definition of VE, circulating
111 subvariants, types and doses of bivalent and reference vaccines, time from vaccination to testing, age group,
112 adjusted VE point estimate and 95% confidence intervals, and confounders adjusted for. When available, the
113 raw numbers of vaccinated and unvaccinated individuals among cases and controls were also recorded.

114 Study quality and risk of bias of each study were independently assessed by three researchers using
115 the Newcastle-Ottawa Scale (NOS). Studies were assigned up to 9 points according to participant selection (4
116 points), study comparability (1 point), and outcome of interest (4 points). A score >7 was considered as high
117 quality, 5–6 as medium, and <5 as low, and studies classified as low quality were excluded from the meta-
118 analysis. Publication bias was also evaluated by Egger’s test, Begg and Mazumdar rank correlation, and funnel
119 plots when at least ten studies were available, with statistical significance achieved if p-value < 0.1. Upon
120 detection of publication bias, we used the Duval and Tweedie trim-and-fill method [18] to adjust the analysis,
121 where missing effect sizes were imputed to achieve symmetry.

122

123 ***Data Synthesis and Analysis***

124 We grouped bivalent VEs into three categories based on the reference arm: (1) unvaccinated, (2) two
125 doses of monovalent vaccines, and (3) three or more doses of monovalent vaccines. This categorization aimed
126 to assess VE variations across different previous vaccination benchmarks. Notably, due to the recent
127 introduction of bivalent vaccines, most VE estimates from the studies we gathered pertain to short-term
128 effects, typically within 120 days. If a study reported VE estimates for more granular time intervals than
129 desired, we combined these estimates using an inverse variance weighted (IVW) averaging method to
130 synthesize a VE estimate for the desired time interval. For example, if a study reported VE estimates for age
131 groups 60–69 years, 70–79 years and ≥80 years old, we synthesize the three VE estimates into a single
132 measure for individuals aged ≥60 years old. We evaluated VE for the entire vaccine-eligible population,
133 pooling all age groups, and specifically for senior adults aged 60 and above. We assessed VE against the
134 Omicron subvariants for both infections and severe outcomes. We did not distinguish between any infection
135 and symptomatic infection, even though some studies focused on the latter; the implications of this approach
136 are discussed. Severe outcomes are defined as hospitalization or death. We did not differentiate between the
137 two types/manufacturers of bivalent vaccines as most studies reported combined VE for these vaccines.

138 To increase sample size, we pooled VE estimates from both test-negative studies and cohort studies.
139 Test-negative studies used either conditional logistic regression or multivariate logistic regression with
140 calendar time adjustment, whereas cohort studies mostly used Cox regression. Notably, simulation results in a
141 previous study showed that logistic regression adjusting for calendar time closely approximated conditional
142 logistic regression matched on calendar time, and the latter shares the same form as the partial likelihood of
143 Cox regression [19]. In cases where studies did not directly report VE but provided Odds Ratios (OR) or
144 Hazard Ratios (HR), VE was derived using the formulas: $(1 - OR) \times 100\%$ or $(1 - HR) \times 100\%$, respectively.
145 We computed pooled VE estimates and their corresponding 95% confidence intervals using a random-effect
146 meta-analysis with restricted maximum likelihood estimation. To assess between-study heterogeneity, we
147 employed the I^2 statistic, with thresholds of 25%, 50%, and 75% denoting low, moderate, and high

148 heterogeneity, respectively. All statistical procedures and visual representations were conducted using the
149 *metafor* R package (version 4.0.5) [20].

150
151

152 **Results**

153 *Study selection and characteristics*

154 We obtained 630 articles from all searched databases (18 from PubMed, 6 from Web of Science, 29
155 from Embase, 425 from Scopus, 2 from Cochrane Library, 46 from medRxiv, 4 from bioRxiv, and 100 from
156 Google Scholar). After removing duplicates, 539 articles remained, of which 87 passed the screening of title,
157 abstracts and keywords and underwent full text review. After further quality control such as removing
158 duplicates and special populations, of these 87 articles as well as 2 additional articles identified through
159 reference lists of eligible articles, 28 articles [13–15,21–45] were formally included in this meta-analysis
160 (Figure 1).

161 Among the 28 papers, nine studies were conducted in the U.S., three in the U.K., three in Italy, two in
162 each of Canada, Japan, Korea, one in each of France, Israel, Netherlands, Norway, Qatar and Singapore, and a
163 multi-national study conducted across Denmark, Finland, Norway, and Sweden. There were 12 test-negative
164 design studies and 16 cohort studies. Regarding the Omicron subvariants in circulation, 20, 13, and 16 studies
165 involved BA.4/5, BQ, and XBB lineages, respectively. Most studies reported multiple VE estimates, stratified
166 by the type of vaccine or the type of outcome. In total, there were 456 VE estimates, including 219 for the
167 BA.1 bivalent booster, 191 for BA.4/5 bivalent booster, and 46 for mixed cohorts receiving BA.1 or BA.4/5
168 bivalent boosters. By the type of outcome, 36, 64, and 356 VE estimates were reported for symptomatic
169 infection, any infection, and severe events, respectively. After screening and synthesizing VE estimates, 20
170 were available for calculating the pooled VE against symptomatic or any infection and 31 for the pooled VE
171 against severe outcomes. In all included studies, the number of doses of bivalent boosters are greater or equal
172 to the number of doses of the reference vaccination regimens, which included unvaccinated, monovalent full
173 course (two doses of monovalent vaccines), and monovalent boosters (3–4 doses of monovalent vaccines).

174

175 *Vaccine effectiveness against Omicron symptomatic infection or any infection*

176 The VE estimates for the bivalent boosters against Omicron symptomatic or any infection were
177 summarized for all age groups combined in Figure 2 and for seniors aged 60 years or older in Figure 3. Only
178 two studies reported a bivalent booster VE with unvaccinated as the reference, with a large inter-study
179 difference, and the combined VE was 53.5% (95% CI: -22.2–82.3%) for adults aged 16 or over (Fig. 2). When
180 the reference was monovalent full course (2 monovalent doses), the pooled bivalent VE from seven studies
181 was 30.8% (95% CI: 22.5–38.2%) for all ages. When the reference was monovalent boosters (3 or more
182 monovalent doses), the pooled bivalent VE from seven studies was estimated to be 41.8% (95% CI: 9.0–

183 62.8%) for all adults ≥ 18 years (Fig. 2). The large uncertainty of this VE estimate came from the study of Tan
184 et al. (2023) in Singapore which reported a VE against symptomatic infection of 83.0% with a tight 95% CI of
185 82.0–84.0%, much higher than the other studies (I^2 statistic=99%). After excluding this study, the pooled VE
186 for all ages was 28.4% (95% CI: 10.2–42.9%). For seniors over 60, one study in the U.S., Rudolph, et al.
187 (2023), reported bivalent VE estimates against the unvaccinated and those with ≥ 2 monovalent doses as 22.5%
188 (95% CI: 16.8–39.8%) and 31.4% (95% CI: 27.7–35.0%), respectively (Fig. 3). When considering ≥ 3
189 monovalent doses as a reference, the pooled VE from four studies was 49.0% (95% CI: -2.1–74.5%), but
190 excluding Tan et al. (2023), it was 30.6% (95% CI: -13.2–57.5%). Combining all three reference vaccination
191 groups, the pooled overall VE against symptomatic or any infection was estimated to be 38.7% (95% CI:
192 23.6–50.8%) for all ages and 42.5% (95% CI: 8.6–63.9%) for adults aged 60 years or older or, if excluding the
193 Singapore study, 32.4% (95% CI: 22.6–41.0%) for all ages and 29.3% (95% CI: 7.2–46.1%, 5 studies) for
194 seniors (Fig. 3).

195

196 *Vaccine Effectiveness against Omicron-associated Severe Events*

197 The pooled bivalent VE estimates against Omicron-associated severe events for all ages were 72.9%
198 (95% CI: 60.5–82.4%, 7 studies), 57.6% (95% CI: 42.4–68.8%, 8 studies), and 68.5% (95% CI: 56.4–77.2%,
199 10 studies) when the reference group was unvaccinated, ≥ 2 monovalent doses, and ≥ 3 monovalent doses,
200 respectively (Fig. 4). In the third category, the pooled VE excluding Tan et al. (2023), which also reported a
201 higher VE estimate against severe events than the rest studies, was 62.1% (95% CI: 54.6–68.3%, 9 studies).
202 Combining the three reference groups, the overall pooled VE against severe events was estimated to be 66.5%
203 (95% CI: 59.2–72.6%, 25 studies) for all ages, or 64.7% (95% CI: 57.7–70.6%, 24 studies) when excluding
204 Tan et al. (2023). For those aged 60 or over, the pooled bivalent VE estimates were 72.0% (95% CI: 51.4–
205 83.9%, 4 studies), 63.4% (95% CI: 41.0–77.3%, 3 studies), and 60.7% (95% CI: 52.4–67.6%, 8 studies) when
206 the reference group was unvaccinated, ≥ 2 monovalent doses, and ≥ 3 monovalent doses, respectively (Fig. 5).
207 The pooled bivalent VE estimates combining all reference groups was 65.2% (95% CI: 57.4–71.5%, 15
208 studies) for senior adults.

209

210 *Assessment of Publication Bias*

211 The only detected publication bias was in the pooled estimate of the overall VE of the bivalent
212 boosters against severe events in all age groups (Egger's test $p = 0.097$, Begg's test $p = 0.236$) as shown in
213 Figure 6. Results were corrected for these biases using the trim-and-fill method.

214

215 **Discussion**

216 In this systematic review and meta-analysis, we synthesized the available evidence from 28 studies,
217 involving 55,393,303 individuals. We found that the bivalent COVID-19 booster doses (vaccinated as the third

218 or subsequent doses) in addition to the previous COVID-19 vaccine series provided about 30-50% VE against
219 infection or symptomatic infection with Omicron subvariants, in reference to unvaccinated or monovalent dose
220 regimens. The bivalent VE against severe clinical outcomes appeared to be more robust, reaching 60-70% for
221 various reference groups. These results underscore the importance of swift adaption of vaccine development to
222 the evolutionary path of the SARS-CoV-2 family. These real-world findings resonate with early
223 immunogenicity studies showing higher antibody responses induced by the bivalent vaccines compared to the
224 monovalent vaccines [46–48].

225 A notable observation from our analysis is that the bivalent vaccine efficacies among individuals aged
226 ≥ 60 years were similar to those among the general population. For symptomatic or any infection, the VE
227 estimates for bivalent vs. ≥ 3 monovalent (excluding the Singapore study) were 28.4% for all ages and 30.6%
228 for seniors. For severe outcomes, the VE estimates for bivalent were comparable between all ages and ≥ 60
229 years regardless of the reference group, e.g., 72.9% and 72.0% for bivalent vs. unvaccinated, and 57.6% and
230 63.4% for bivalent vs. ≥ 2 monovalent. The VE of bivalent vs. ≥ 3 monovalent doses was also comparable
231 between the two age profiles (62.1% after excluding the Singapore study vs. 60.7%). However, with most
232 studies (8 out of 10) for all-age VE estimates conducted among seniors, this similarity could be partly
233 attributed to the similarity in age profiles. Given that the senior age group is the most vulnerable to severe
234 outcomes from COVID-19 [49], our findings suggest we should continue to prioritize the older subpopulation
235 for coverage with bivalent vaccines.

236 Compared to three or more doses of a monovalent vaccine, the bivalent booster vaccines demonstrated
237 superior relative efficacies against both infection (VE=28–42% depending on excluding or including the
238 Singapore study) and severe disease (VE=68.5%) during the circulation of the BA.4, BA.5, and subsequent
239 Omicron subvariants. This superiority can also be seen by calculating the relative efficacy of three or more
240 doses of monovalent vs. unvaccinated. For example, in terms of severe disease, the relative efficacy of three or
241 more doses of monovalent vs. unvaccinated is $1 - \frac{1-0.729}{1-0.685} = 0.14$, much lower than the relative efficacy of the
242 bivalent booster vs. unvaccinated, 0.729.

243 Our study has several limitations. First, our analysis was constrained by the lack of long-term data,
244 limiting our ability to assess the potential waning of VE over time. Some studies have shown the efficacy of
245 the bivalent booster dose waned over time, similar to the monovalent booster doses [14,50], but the VE against
246 severe outcomes generally wanes at a much slower rate than that against infection. Second, a few studies
247 found prior infection could modify the efficacies of monovalent or bivalent boosters [37,50], but we were
248 unable to stratify the VE estimates by prior infection status as most studies did not provide such information.
249 Third, many studies included in this meta-analysis [21,22,29,32] did not specify the manufacturer or type of
250 the bivalent booster and monovalent doses, introducing additional heterogeneity into and thus complicating the
251 interpretation of our pooled results. This lack of granularity emphasizes the need for future studies to report

252 VE estimates with greater specificity. Finally, we had to synthesize desired VE measures from multiple VE
253 estimates in the same study, e.g., deriving the VE for the age group of 60 years or more from VE estimates for
254 finer age groups. Such synthesis did not consider potential correlation among the finer estimates, which could
255 result in under-evaluation of uncertainty in the synthesized VE estimate.

256 In conclusion, our study presents a systematic and up-to-date picture of the protective benefits of
257 bivalent COVID-19 booster doses against Omicron subvariants, particularly against severe clinical outcomes.
258 The SARS-CoV-2 pandemic continues to evolve with newly emerging variants that can better evade the
259 current immunity landscape of the population but are not necessarily more pathogenic, e.g., HV.1 and JN.1
260 Omicron lineages have dominated previous strains in many places. While updated vaccines are rolling out at a
261 slower pace, their strong protection against severe disease induced by the new strains has saved millions of
262 lives and guards our daily life from interruption. On the other hand, as of September 2023, the coverage of
263 bivalent vaccines in the U.S. remained below 50% even among people aged ≥ 60 years, according to the U.S.
264 CDC. In September 2023, US CDC recommended vaccination with XBB-containing vaccines among persons
265 aged ≥ 6 months [51]. In addition to developing more potent and convenient vaccines such as the flu-Covid
266 combo vaccines, more resources should be directed to campaign the effectiveness and safety of existing
267 bivalent vaccines, especially among the vulnerable subpopulations. Finally, we encourage future research on
268 vaccine effectiveness assessment to provide more granular VE data and to monitor the long-term safety and
269 effectiveness of bivalent/multivalent vaccines.

270

271 **Author Contributions**

272 SSong, ZM, YY and IL conceived the study. SSong and ZM collected the data, SSong, ZM, ML, YM,
273 SX, YH, SSarkar, AC and YY reviewed the data. SSong analyzed data under the supervision of YY, ZM and
274 IL. SSong, ZM and YY drafted the manuscript. All authors contributed to interpretation of results. SSong, YY,
275 ZM and IL finalized the manuscript.

276

277 **Conflicts of Interest**

278 The authors declare that the research was conducted in the absence of any commercial or financial
279 relationships that could be construed as a potential conflict of interest.

280

281 **Data Sharing**

282 The raw summary-level data were derived from publicly available papers cited in the reference.
283 Extracted data and programming codes will be made available upon request by email to the corresponding
284 author.

285

286 **Funding/Support**

287 SSong, YY and IL were supported by US CDC grant U01 CK000670.

288

289 **Role of the Funding Source**

290 The funders had no role in study design, data collection, data analysis, data interpretation, or the
291 writing of the report.

292 **References**

- 293 1. Zheng C, Shao W, Chen X, Zhang B, Wang G, Zhang W. Real-world effectiveness of COVID-19 vaccines: a
294 literature review and meta-analysis. *International Journal of Infectious Diseases* **2022**; 114:252–260.
- 295 2. Ssentongo P, Ssentongo AE, Voleti N, et al. SARS-CoV-2 vaccine effectiveness against infection,
296 symptomatic and severe COVID-19: a systematic review and meta-analysis. *BMC Infectious Diseases*
297 **2022**; 22:439.
- 298 3. Song S, Madewell ZJ, Liu M, Longini IM, Yang Y. Effectiveness of SARS-CoV-2 vaccines against Omicron
299 infection and severe events: a systematic review and meta-analysis of test-negative design studies.
300 *Frontiers in Public Health* **2023**; 11. Available at:
301 <https://www.frontiersin.org/articles/10.3389/fpubh.2023.1195908>. Accessed 8 October 2023.
- 302 4. Menegale F, Manica M, Zardini A, et al. Evaluation of Waning of SARS-CoV-2 Vaccine–Induced
303 Immunity: A Systematic Review and Meta-analysis. *JAMA Network Open* **2023**; 6:e2310650.
- 304 5. Madewell ZJ, Yang Y, Longini IM Jr, Halloran ME, Dean NE. Household Secondary Attack Rates of SARS-
305 CoV-2 by Variant and Vaccination Status: An Updated Systematic Review and Meta-analysis. *JAMA*
306 *Network Open* **2022**; 5:e229317.
- 307 6. Chatterjee S, Bhattacharya M, Nag S, Dhama K, Chakraborty C. A Detailed Overview of SARS-CoV-2
308 Omicron: Its Sub-Variants, Mutations and Pathophysiology, Clinical Characteristics, Immunological
309 Landscape, Immune Escape, and Therapies. *Viruses* **2023**; 15:167.
- 310 7. Wang Q, Guo Y, Iketani S, et al. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4
311 and BA.5. *Nature* **2022**; 608:603–608.
- 312 8. Planas D, Bruel T, Staropoli I, et al. Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to
313 neutralizing antibodies. *Nat Commun* **2023**; 14:824.
- 314 9. Hyun H-J, Choi M-J, Nham E, et al. Neutralizing Activity against BQ.1.1, BN.1, and XBB.1 in Bivalent
315 COVID-19 Vaccine Recipients: Comparison by the Types of Prior Infection and Vaccine Formulations.
316 *Vaccines* **2023**; 11:1320.
- 317 10. Davis-Gardner ME, Lai L, Wali B, et al. Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA
318 Bivalent Booster. *N Engl J Med* **2023**; 388:183–185.
- 319 11. Rosenblum HG. Interim Recommendations from the Advisory Committee on Immunization Practices for
320 the Use of Bivalent Booster Doses of COVID-19 Vaccines — United States, October 2022. *MMWR Morb*
321 *Mortal Wkly Rep* **2022**; 71. Available at: <https://www.cdc.gov/mmwr/volumes/71/wr/mm7145a2.htm>.
322 Accessed 8 October 2023.
- 323 12. Commissioner O of the. Coronavirus (COVID-19) Update: FDA Authorizes Moderna, Pfizer-BioNTech
324 Bivalent COVID-19 Vaccines for Use as a Booster Dose. FDA, 2022. Available at:
325 [https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-](https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-moderna-pfizer-biontech-bivalent-covid-19-vaccines-use)
326 [moderna-pfizer-biontech-bivalent-covid-19-vaccines-use](https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-moderna-pfizer-biontech-bivalent-covid-19-vaccines-use). Accessed 8 October 2023.
- 327 13. Chae C, Kim RK, Jang EJ, et al. Comparing the effectiveness of bivalent and monovalent COVID-19
328 vaccines against COVID-19 infection during the winter season of 2022-2023: A real-world retrospective

- 329 observational matched cohort study in the Republic of Korea. *International Journal of Infectious*
330 *Diseases* **2023**; 135:95–100.
- 331 14. Lin D-Y, Xu Y, Gu Y, Zeng D, Sunny SK, Moore Z. Durability of Bivalent Boosters against Omicron
332 Subvariants. *New England Journal of Medicine* **2023**; 388:1818–1820.
- 333 15. Link-Gelles R, Weber ZA, Reese SE, et al. Estimates of Bivalent mRNA Vaccine Durability in Preventing
334 COVID-19-Associated Hospitalization and Critical Illness Among Adults with and Without
335 Immunocompromising Conditions - VISION Network, September 2022-April 2023. *MMWR Morb Mortal*
336 *Wkly Rep* **2023**; 72:579–588.
- 337 16. Meah S, Shi X, Fritsche LG, et al. Design and analysis heterogeneity in observational studies of COVID-19
338 booster effectiveness: A review and case study. *Science Advances* **2023**; 9:eadj3747.
- 339 17. Methley AM, Campbell S, Chew-Graham C, McNally R, Cheraghi-Sohi S. PICO, PICOS and SPIDER: a
340 comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews.
341 *BMC Health Serv Res* **2014**; 14:579.
- 342 18. Duval S, Tweedie R. Trim and Fill: A Simple Funnel-Plot–Based Method of Testing and Adjusting for
343 Publication Bias in Meta-Analysis. *Biometrics* **2000**; 56:455–463.
- 344 19. BOND HS, SULLIVAN SG, COWLING BJ. Regression approaches in the test-negative study design for
345 assessment of influenza vaccine effectiveness. *Epidemiol Infect* **2016**; 144:1601–1611.
- 346 20. Viechtbauer W. Conducting Meta-Analyses in R with the metafor Package. *Journal of Statistical*
347 *Software* **2010**; 36:1–48.
- 348 21. Andersson NW, Thiesson EM, Baum U, et al. Comparative effectiveness of bivalent BA.4-5 and BA.1
349 mRNA booster vaccines among adults aged ≥ 50 years in Nordic countries: nationwide cohort study.
350 *BMJ* **2023**; 382:e075286.
- 351 22. Arashiro T, Arima Y, Kuramochi J, et al. Effectiveness of BA.1- and BA.4/BA. 5-Containing Bivalent
352 COVID-19 mRNA Vaccines Against Symptomatic SARS-CoV-2 Infection During the BA.5-Dominant Period
353 in Japan. *Open Forum Infect Dis* **2023**; 10:ofad240.
- 354 23. Arbel R, Peretz A, Sergienko R, et al. Effectiveness of a bivalent mRNA vaccine booster dose to prevent
355 severe COVID-19 outcomes: a retrospective cohort study. *The Lancet Infectious Diseases* **2023**; 23:914–
356 921.
- 357 24. Auvigne V, Tamandjou Tchuem CR, Schaeffer J, Vaux S, Parent Du Chatelet I. Protection against
358 symptomatic SARS-CoV-2 infection conferred by the Pfizer-BioNTech Original/BA.4-5 bivalent vaccine
359 compared to the mRNA Original monovalent vaccines – A matched cohort study in France. *Vaccine*
360 **2023**; 41:5490–5493.
- 361 25. Chatzilena A, Hyams C, Challen R, et al. Relative vaccine effectiveness of mRNA COVID-19 boosters in
362 people aged at least 75 years during the spring-summer (monovalent vaccine) and autumn-winter
363 (bivalent vaccine) booster campaigns: a prospective test negative case–control study, United Kingdom,
364 2022. *Eurosurveillance* **2023**; 28:2300173.

- 365 26. Chemaitelly H, Ayoub HH, AlMukdad S, et al. Bivalent mRNA-1273.214 vaccine effectiveness against
366 SARS-CoV-2 omicron XBB* infections. *Journal of Travel Medicine* **2023**; 30:taad106.
- 367 27. Fabiani M, Mateo-Urdiales A, Sacco C, et al. Protection against severe COVID-19 after second booster
368 dose of adapted bivalent (original/Omicron BA.4-5) mRNA vaccine in persons ≥ 60 years, by time since
369 infection, Italy, 12 September to 11 December 2022. *Eurosurveillance* **2023a**; 28:2300105.
- 370 28. Grewal R, Buchan SA, Nguyen L, et al. Effectiveness of mRNA COVID-19 Monovalent and Bivalent
371 Vaccine Booster Doses Against Omicron Severe Outcomes Among Adults Aged ≥ 50 Years in Ontario,
372 Canada: A Canadian Immunization Research Network Study. *The Journal of Infectious Diseases* **2023**;
373 :jiad419.
- 374 29. Huiberts AJ, de Gier B, Hoeve CE, et al. Effectiveness of bivalent mRNA booster vaccination against
375 SARS-CoV-2 Omicron infection, the Netherlands, September to December 2022. *Euro Surveill* **2023**;
376 28:2300087.
- 377 30. Kirsebom FCM, Andrews N, Stowe J, Ramsay M, Bernal JL. Duration of protection of ancestral-strain
378 monovalent vaccines and effectiveness of bivalent BA.1 boosters against COVID-19 hospitalisation in
379 England: a test-negative case-control study. *The Lancet Infectious Diseases* **2023a**; 0. Available at:
380 [https://www.thelancet.com/journals/laninf/article/PIIS1473-3099\(23\)00365-1/fulltext](https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00365-1/fulltext). Accessed 30
381 September 2023.
- 382 31. Kirsebom FCM, Harman K, Lunt RJ, et al. Vaccine effectiveness against hospitalisation estimated using a
383 test-negative case-control study design, and comparative odds of hospital admission and severe
384 outcomes with COVID-19 sub-lineages BQ.1, CH.1.1. and XBB.1.5 in England. *The Lancet Regional
385 Health – Europe* **2023b**; 35. Available at: [https://www.thelancet.com/journals/lanepi/article/PIIS2666-
386 7762\(23\)00174-6/fulltext](https://www.thelancet.com/journals/lanepi/article/PIIS2666-7762(23)00174-6/fulltext). Accessed 5 January 2024.
- 387 32. Lee N, Nguyen L, Austin PC, et al. Protection Conferred by COVID-19 Vaccination, Prior SARS-CoV-2
388 Infection, or Hybrid Immunity Against Omicron-Associated Severe Outcomes Among Community-
389 Dwelling Adults. *Clinical Infectious Diseases* **2023**; :ciad716.
- 390 33. Mateo-Urdiales A, Sacco C, Fotakis EA, et al. Relative effectiveness of monovalent and bivalent mRNA
391 boosters in preventing severe COVID-19 due to omicron BA.5 infection up to 4 months post-
392 administration in people aged 60 years or older in Italy: a retrospective matched cohort study. *The
393 Lancet Infectious Diseases* **2023**; Available at:
394 <https://www.sciencedirect.com/science/article/pii/S1473309923003742>. Accessed 1 October 2023.
- 395 34. Shrestha NK, Burke PC, Nowacki AS, Simon JF, Hagen A, Gordon SM. Effectiveness of the Coronavirus
396 Disease 2019 Bivalent Vaccine. *Open Forum Infectious Diseases* **2023**; 10:ofad209.
- 397 35. Stecher M, Kristoffersen AB, Lie K, Andersen SR, Meijerink H, Starrfelt J. Effectiveness and durability of
398 a second COVID-19 booster against severe outcomes among older people in Norway: a population-
399 based cohort study comparing mono- and bivalent booster doses. *International Journal of
400 Epidemiology* **2023**; :dyad114.
- 401 36. Surie D. Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated
402 Hospitalization Among Immunocompetent Adults Aged ≥ 65 Years — IVY Network, 18 States,
403 September 8–November 30, 2022. *MMWR Morb Mortal Wkly Rep* **2022**; 71. Available at:
404 <https://www.cdc.gov/mmwr/volumes/71/wr/mm715152e2.htm>. Accessed 3 October 2023.

- 405 37. Tan CY, Chiew CJ, Pang D, et al. Effectiveness of bivalent mRNA vaccines against medically attended
406 symptomatic SARS-CoV-2 infection and COVID-19-related hospital admission among SARS-CoV-2-naive
407 and previously infected individuals: a retrospective cohort study. *The Lancet Infectious Diseases* **2023**;
408 0. Available at: [https://www.thelancet.com/journals/laninf/article/PIIS1473-3099\(23\)00373-0/fulltext](https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00373-0/fulltext).
409 Accessed 1 October 2023.
- 410 38. Tenforde MW. Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–
411 Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among
412 Immunocompetent Adults — VISION Network, Nine States, September–November 2022. *MMWR Morb*
413 *Mortal Wkly Rep* **2023**; 71. Available at: <https://www.cdc.gov/mmwr/volumes/71/wr/mm7153a1.htm>.
414 Accessed 3 October 2023.
- 415 39. Tseng HF, Ackerson BK, Sy LS, et al. mRNA-1273 bivalent (original and Omicron) COVID-19 vaccine
416 effectiveness against COVID-19 outcomes in the United States. *Nat Commun* **2023**; 14:5851.
- 417 40. Mimura W, Ishiguro C, Terada-Hirashima J, et al. Bivalent Vaccine Effectiveness Among Adults Aged ≥65
418 Years During the BA.5-Predominant Period in Japan: The VENUS Study. *Open Forum Infectious Diseases*
419 **2023**; 10:ofad475.
- 420 41. Tartof SY, Slezak JM, Puzniak L, et al. Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against
421 a range of COVID-19 outcomes in a large health system in the USA: a test-negative case–control study.
422 *The Lancet Respiratory Medicine* **2023**; 11:1089–1100.
- 423 42. Rudolph AE, Khan FL, Shah A, et al. Effectiveness of BNT162b2 BA.4/5 Bivalent mRNA Vaccine Against
424 Symptomatic COVID-19 Among Immunocompetent Individuals Testing at a Large US Retail Pharmacy.
425 *The Journal of Infectious Diseases* **2023**; :jjad474.
- 426 43. Fabiani M, Mateo-Urdiales A, Sacco C, et al. Relative effectiveness of bivalent Original/Omicron BA.4-5
427 mRNA vaccine in preventing severe COVID-19 in persons 60 years and above during SARS-CoV-2
428 Omicron XBB.1.5 and other XBB sublineages circulation, Italy, April to June 2023. *Euro Surveill* **2023b**;
429 28:2300397.
- 430 44. Kim RK, Choe YJ, Jang EJ, et al. Comparative Effectiveness of COVID-19 Bivalent Versus Monovalent
431 mRNA Vaccines in the Early Stage of Bivalent Vaccination in Korea: October 2022 to January 2023. *J*
432 *Korean Med Sci* **2023**; 38:e396.
- 433 45. Plumb ID, Briggs Hagen M, Wiegand R, et al. Effectiveness of a bivalent mRNA vaccine dose against
434 symptomatic SARS-CoV-2 infection among U.S. Healthcare personnel, September 2022–May 2023.
435 *Vaccine* **2023**; Available at: <https://www.sciencedirect.com/science/article/pii/S0264410X23012872>.
436 Accessed 4 January 2024.
- 437 46. Chalkias S, Harper C, Vrbicky K, et al. A Bivalent Omicron-Containing Booster Vaccine against Covid-19.
438 *New England Journal of Medicine* **2022**; 387:1279–1291.
- 439 47. Springer DN, Bauer M, Medits I, et al. Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5)
440 increases neutralization of matched Omicron variants. *npj Vaccines* **2023**; 8:1–4.
- 441 48. Chen S-Y, Lin C-Y, Chi H, et al. The Effectiveness of Bivalent COVID-19 Vaccination: A Preliminary Report.
442 *Life* **2023**; 13:2094.

- 443 49. Sadarangani M, Abu Raya B, Conway JM, et al. Importance of COVID-19 vaccine efficacy in older age
444 groups. *Vaccine* **2021**; 39:2020–2023.
- 445 50. Lin D-Y, Gu Y, Xu Y, et al. Association of Primary and Booster Vaccination and Prior Infection With SARS-
446 CoV-2 Infection and Severe COVID-19 Outcomes. *JAMA* **2022**; 328:1415–1426.
- 447 51. Regan JJ. Use of Updated COVID-19 Vaccines 2023–2024 Formula for Persons Aged ≥ 6 Months:
448 Recommendations of the Advisory Committee on Immunization Practices — United States, September
449 2023. *MMWR Morb Mortal Wkly Rep* **2023**; 72. Available at:
450 <https://www.cdc.gov/mmwr/volumes/72/wr/mm7242e1.htm>. Accessed 13 October 2023.

451

452

453 **Figure Legend**

454 Figure 1. Summary of evidence search and selection.

455

456 Figure 2. Forest plot for relative effectiveness of bivalent vaccines compared to different reference vaccine
457 groups against any infection or symptomatic infection for all ages. Statistics Cochran's Q, I^2 and τ^2 measure
458 the heterogeneity between studies. End points of the studies are either symptomatic infection (SI) or any
459 infection (AI). TND: test-negative design study. cohort: cohort study. NA: not applicable. Mixed: containing
460 non-mRNA and mRNA monovalent vaccines. $\geq 2^*$: the majority ($\geq 80\%$) received 2 or more doses.

461

462 Figure 3. Forest plot for relative effectiveness of bivalent vaccines compared to different reference vaccine
463 groups against any infection or symptomatic infection for senior adults ≥ 60 years old. Statistics Cochran's Q,
464 I^2 and τ^2 measure the heterogeneity between studies. End points of the studies are either symptomatic
465 infection (SI) or any infection (AI). TND: test-negative design study. cohort: cohort study. NA: not applicable.
466 Mixed: containing non-mRNA and mRNA monovalent vaccines.

467

468 Figure 4. Forest plot for relative effectiveness of bivalent vaccines compared to different reference vaccine
469 groups against severe outcomes for all ages. Statistics Cochran's Q, I^2 and τ^2 measure the heterogeneity
470 between studies. End points of the studies are hospitalization (H), Death (D), hospitalization or death (H/D),
471 severe disease or death (SD/D). TND: test-negative design study. cohort: cohort study. NA: not applicable. NS:
472 not specified. Mixed: containing non-mRNA and mRNA monovalent vaccines.

473

474 Figure 5. Forest plot for relative effectiveness of bivalent vaccines compared to different reference vaccine
475 groups against severe outcomes for senior adults ≥ 60 years old. Statistics Cochran's Q, I^2 and τ^2 measure the
476 heterogeneity between studies. End points of the studies are hospitalization (H), Death (D), hospitalization or
477 death (H/D), severe disease or death (SD/D). TND: test-negative design study. cohort: cohort study. NA: not
478 applicable. Mixed: containing non-mRNA and mRNA monovalent vaccines.

Identification of studies via databases




Figure 1. Summary of evidence search and selection

Fig 2. Forest Plot for Bivalent COVID-19 Vaccines Effectiveness against All Infection or Symptomatic Infection, All Ages




Fig 3. Forest Plot for Bivalent COVID-19 Vaccines Effectiveness against All Infection or Symptomatic Infection, Senior Ages (≥ 60 years old)




Fig 4. Forest Plot for Bivalent COVID-19 Vaccines Effectiveness against Severe Outcomes, All Ages




Fig 5. Forest Plot for Bivalent COVID-19 Vaccines Effectiveness against Severe Outcomes, Senior Ages (≥ 60 years old)

